Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Phillips

Ophthalmology Sewickley, PA Medical Doctor

NPI 1922213107 CMS profile 268502

2591 Wexford Bayne Rd, Suite 104, Sewickley, PA 15143

Open in the dashboard

General payments

$3,492

92 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Phillips of Sewickley, PA is reported in the CMS Open Payments database as having received $3,492 across 92 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,142 27
2024 General $723 30
2023 General $309 14
2022 General $374 6
2021 General $703 7
2020 General $198 6
2019 General $43 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Phillips
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Paul Phillips were reported at $1,142. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Paul Phillips Ophthalmology median Middle half National median
2019 $43 $258 $104–$655 $163
2020 $198 $126 $45–$321 $114
2021 $703 $205 $76–$534 $132
2022 $374 $266 $100–$678 $149
2023 $309 $308 $117–$745 $160
2024 $723 $340 $127–$846 $164
2025 $1,142 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $1,633 64 payments
  2. Ivantis, Inc $722 7 payments
  3. RxSight Inc $531 2 payments
  4. Sight Sciences, Inc. $176 5 payments
  5. Glaukos Corporation $125 2 payments
  6. Bausch & Lomb, a division of Bausch Health US, LLC $119 2 payments
  7. Allergan Inc. $48 3 payments
  8. Bausch & Lomb Americas Inc. $44 2 payments
  9. Carl Zeiss Meditec AG $39 2 payments
  10. TissueTech, Inc. $24 1 payment
  11. Other $32 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,426 87 payments
  2. Consulting Fee $1,000 2 payments
  3. Gift $39 2 payments
  4. Entertainment $27 1 payment
Products named General payments · program years 2019–2025
  1. Hydrus Microstent Ophthalmic Surgery $654 4 payments
  2. RXSIGHT CONTACT LENS $531 2 payments
  3. RXSIGHT INJECTOR CARTRIDGE $531 2 payments
  4. RXSIGHT INJECTOR HANDPIECE $531 2 payments
  5. RXSIGHT LIGHT DELIVERY DEVICE (LDD) $531 2 payments
  6. LIGHT ADJUSTABLE LENS (LAL) $531 2 payments
  7. HYDRUS Microstent Ophthalmology $470 32 payments
  8. Centurion $393 7 payments
  9. Clareon $255 6 payments
  10. OMNI SURGICAL SYSTEM $176 5 payments
  11. Other $1,303 43 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

1,943

Median for Ophthalmology: 891

Drug cost

$51,956

Median for Ophthalmology: $68,233

Branded share of claims

2.2%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisolone Acetate Generic 781 $31,330
Ofloxacin Generic 488 $6,646
Ketorolac Tromethamine Generic 484 $6,472
Fluorometholone Generic 32 $2,410
Brimonidine Tartrate Generic 30 $2,306
Loteprednol Etabonate Generic 12 $849
Valacyclovir Valacyclovir Hcl Brand 16 $701
Moxifloxacin Moxifloxacin Hcl Brand 15 $542
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 11 $203
Tobramycin Generic 24 $182

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$270,332

Of which drugs: $543

Medicare patients

450

Average age 73

Services billed

1,619

277 women, 173 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 43%
Ischemic heart disease 19%
Diabetes 18%
Chronic kidney disease 17%
Cancer 16%
Osteoporosis 16%
Depression 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, moxifloxacin, 100 mg J2280 Office 45 78 $543

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

92 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record